Publications by authors named "Alyson Simonds"
Article Synopsis
- A study evaluated 328 patients with hormone receptor-positive, HER2/neu-negative breast cancer, consisting of 34.8% African American (AA) and 65.2% White American (WA) participants.
- The average age of patients was 60 years, with similar tumor sizes between AA (1.6 cm) and WA (1.7 cm), although AA had a higher average BMI (33 vs. 29.8).
- Distant recurrence rates were low for both groups (1.0% for AA and 1.6% for WA), indicating that the recurrence score (RS) utility is comparable between AA and WA patients, despite no significant differences in chemotherapy delivery.
Introduction: The 21-gene expression profile [Oncotype DX Recurrence Score (RS)] stratifies benefit from adjuvant chemotherapy in hormone receptor (HR)-positive, HER2/neu-negative, node-negative breast cancer. It is not routinely applied to predict neoadjuvant chemotherapy (NACT) response; data in diverse patient populations also are limited. We developed a statistical model based on standard clinicopathologic features to identify high-risk cases (RS > 30) and then evaluated ability of predicted high RS to predict for NACT downstaging.
View Article and Find Full Text PDF